29,572 Shares in Celldex Therapeutics, Inc. $CLDX Bought by Ellsworth Advisors LLC

Ellsworth Advisors LLC purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 29,572 shares of the biopharmaceutical company’s stock, valued at approximately $958,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Mirador Capital Partners LP grew its stake in shares of Celldex Therapeutics by 6.7% in the third quarter. Mirador Capital Partners LP now owns 193,267 shares of the biopharmaceutical company’s stock worth $6,264,000 after purchasing an additional 12,213 shares in the last quarter. Engineers Gate Manager LP acquired a new position in shares of Celldex Therapeutics during the second quarter valued at $1,259,000. Arizona State Retirement System raised its stake in shares of Celldex Therapeutics by 13.0% during the second quarter. Arizona State Retirement System now owns 18,565 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 2,139 shares in the last quarter. Nykredit A S bought a new stake in shares of Celldex Therapeutics during the second quarter valued at about $67,000. Finally, Corient Private Wealth LP raised its stake in shares of Celldex Therapeutics by 1,109.0% during the second quarter. Corient Private Wealth LP now owns 176,956 shares of the biopharmaceutical company’s stock valued at $6,585,000 after purchasing an additional 162,320 shares in the last quarter.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $28.93 on Friday. Celldex Therapeutics, Inc. has a twelve month low of $22.10 and a twelve month high of $45.14. The firm has a 50-day moving average of $36.84 and a two-hundred day moving average of $34.86.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.12. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.73 million. Equities analysts predict that Celldex Therapeutics, Inc. will post -4.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on CLDX shares. Wall Street Zen upgraded shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Wells Fargo & Company increased their price objective on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Friday, July 17th. Barclays raised their price objective on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Guggenheim boosted their target price on Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.92.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.